Surfacide Peer-Reviewed Study: Confirms UV-C Extremely Effective in Killing SARS-CoV-2 On Surfaces and Air in Environments

Surfacide notes A recent peer-reviewed studyin the Journal of Clinical Anesthesia* found the Surfacide Helios System UV-C technology is nearly 95% effective in preventing SARS CoV-2 in patient environments.

This is the first clinical study that evaluates the use of UV-C in operating rooms, compared to previous studies conducted in a controlled lab environment.

The study was led by Dr. Randy Loftus, MD, an Associate Professor of Anesthesiology and Critical Care Medicine at University of Iowa Hospital and Clinics, and Dr. Franklin Dexter, MD, PhD, University of Iowa Professor in the Department of Anesthesia. Dr. Loftus has received national and international recognition for his expertise regarding the epidemiology of intraoperative pathogen transmission. View the study here.

In the last 10 years he has made numerous contributions to science as is reflected in a solid body of published evidence, including a focus on infection prevention protocols in the perioperative space. Dr. Dexter and his colleagues have developed much of the science in anesthesia group and operating room management.

For this study, Surfacide’s Helios System was deployed—the world’s first and only patented trio of UV light-emitting ‘robots’ that simultaneously provide floor to ceiling UV-C energy. A total of 473 intraoperative reservoir samples were tested among 13 anesthesia work areas and 12 environmental locations. The following results were confirmed:

  • Environmental locations tested monitored proximal sites exposed to droplet spread and more distal sites potentially impacted by aerosolized particles.
  • Use of Surfacide UV-C disinfection showed nearly a 2-fold reduction in SARS-CoV-2 detection as compared to traditional surface disinfection cleaning procedures without UV-C.
  • Surface disinfection cleaning alone is associated with greater environmental detection of SARS-CoV-2.
  • The Surfacide technology was associated with decreased residual contamination of distal sites impacted by aerosolization.

“This study further validates Surfacide’s effectiveness as a critical infection control measure in combating deadly pathogens in real world environments,” said Surfacide Founder and CEO Gunner Lyslo. “Surfacide’s triple-emitter, floor to ceiling UV technology, along with its effectiveness in inactivating aerosolized pathogens AND pathogens colonizing surfaces, makes this study a game-changer in infection prevention and confirms that not all UV-C is created equal.”

The data presented in this paper emphasizes the importance of Surfacide UV-C as an infection control measure against pathogens found on surfaces and in the air, especially within the operating room space. Surfacide’s evidence-based approach is critical in providing a safer environment for healthcare staff and patients alike. It’s proven ability, as documented in this study, sets this technology apart from all other UV devices.

*R.W. Loftus, F. Dexter, L.C. Evans, et al., An assessment of the impact of recommended anesthesia work area cleaning procedures on intraoperative SARS-CoV-2 contamination, a case-series analysis, Journal of Clinical Anesthesia (2021)

 

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution